Harling; John David
Patent Applications and Registrations
Patent applications and USPTO patent grants for Harling; John David.The latest application filed is for "novel compounds".
Company Profile
10.15.27
- Harling; John David - Stevenage GB
- HARLING; John David - Hertfordshire GB
- Harling; John David - Herfordshire GB
- Harling; John David - Harlow GB
- Harling, John David - Herts GB
- Harling, John David - Sawbridgeworth GB
- Harling, John David - Harlow Essex GB
Patent Activity
| Patent | Date |
|---|---|
| Conjugates comprising RIPK2 inhibitors Grant 10,781,205 - Casillas , et al. Sept | 2020-09-22 |
| Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase Grant 10,730,862 - Crews , et al. | 2020-08-04 |
| Novel Compounds App 20190382381 - CASILLAS; Linda N. ; et al. | 2019-12-19 |
| Compounds Grant 10,435,391 - Casillas , et al. O | 2019-10-08 |
| Novel Compounds App 20190263798 - HARLING; John David ; et al. | 2019-08-29 |
| Novel Compounds App 20190210996 - HARLING; John David ; et al. | 2019-07-11 |
| 1AP E3 ligase directed proteolysis targeting chimeric molecules Grant 10,336,744 - Harling , et al. | 2019-07-02 |
| Novel Compounds App 20190152946 - HARLING; John David ; et al. | 2019-05-23 |
| Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase App 20190127359 - CREWS; CRAIG M. ; et al. | 2019-05-02 |
| Conjugates Comprising Ripk2 Inhibitors App 20190119271 - CASILLAS; Linda N. ; et al. | 2019-04-25 |
| Compounds Grant 9,993,514 - Campos , et al. June 12, 2 | 2018-06-12 |
| Benzothiophene derivatives as estrogen receptor inhibitors Grant 9,988,376 - Campos , et al. June 5, 2 | 2018-06-05 |
| lAP E3 LIGASE DIRECTED PROTEOLYSIS TARGETING CHIMERIC MOLECULES App 20180118733 - HARLING; John David ; et al. | 2018-05-03 |
| Benzothiophene Derivatives As Estrogen Receptor Inhibitors App 20160368911 - CAMPOS; Sebastien Andre ; et al. | 2016-12-22 |
| Novel Compounds App 20160136230 - CAMPOS; Sebastien Andre ; et al. | 2016-05-19 |
| Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase App 20140356322 - Crews; Craig M. ; et al. | 2014-12-04 |
| Pyrimidine Derivatives Used As Itk Inhibitors App 20120058984 - Alder; Catherine Mary ; et al. | 2012-03-08 |
| 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors App 20090099231 - Harling; John David ; et al. | 2009-04-16 |
| 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors App 20080306045 - Camus; Laure ; et al. | 2008-12-11 |
| N-(1-(2,3-Dihydro-1H-Inden-5Yl)-2-Oxo-3-Pyrrolidinyl)-Sulfonamide Derivatives for Use as Factor Xa Inhibitors App 20070249705 - Harling; John David ; et al. | 2007-10-25 |
| Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease App 20070155805 - Harling; John David ; et al. | 2007-07-05 |
| 3-sulfonylamino-pyrrolidine-2-one derivatives as inhibitors of factor Xa Grant 7,235,544 - Borthwick , et al. June 26, 2 | 2007-06-26 |
| Chemical compounds Grant 7,199,239 - Beswick , et al. April 3, 2 | 2007-04-03 |
| Compounds Grant 7,105,536 - Harling , et al. September 12, 2 | 2006-09-12 |
| 3-Sulfonylamino-pyrrolindine -2- one derivatives as inhibitors of factor xa App 20060178419 - Borthwick; Alan David ; et al. | 2006-08-10 |
| Chemical compounds App 20060074111 - Beswick; Paul John ; et al. | 2006-04-06 |
| Triarylimidazole derivatives as cytokine inhibitors Grant 6,906,089 - Gaster , et al. June 14, 2 | 2005-06-14 |
| Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase App 20050014938 - Gaster, Laramie Mary ; et al. | 2005-01-20 |
| Thiazolyl substituted triazoles as alk5 inhibitors App 20040266842 - Gaster, Laramie Mary ; et al. | 2004-12-30 |
| Pyridinylimidazoles App 20040220230 - Gaster, Laramie Mary ; et al. | 2004-11-04 |
| Pyridyl-substituted triazoles as tgf inhibitors App 20040152738 - Gaster, Laramie Mary ; et al. | 2004-08-05 |
| Compounds Grant 6,770,657 - Harling , et al. August 3, 2 | 2004-08-03 |
| Novel compounds App 20040142964 - Harling, John David ; et al. | 2004-07-22 |
| Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity Grant 6,762,192 - Harling , et al. July 13, 2 | 2004-07-13 |
| Pyridinylimidazoles App 20030166633 - Gaster, Laramie Mary ; et al. | 2003-09-04 |
| Triarylimidazole derivatives as cytokine inhibitors App 20030149277 - Gaster, Laramie Mary ; et al. | 2003-08-07 |
| Novel compounds App 20030036551 - Harling, John David ; et al. | 2003-02-20 |
| Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity App 20020143029 - Harling, John David ; et al. | 2002-10-03 |
| Substituted isoquinoline derivatives and their use as anticonvulsants App 20010025045 - Edwards, Peter David ; et al. | 2001-09-27 |
| 1,6-naphthyridine anti-convulsants Grant 6,245,778 - Hadley , et al. June 12, 2 | 2001-06-12 |
| Enantiomers of 1-(3,4-dichlorobenzyl)-2-methylaminoindane Grant 5,863,952 - Orlek , et al. January 26, 1 | 1999-01-26 |
| Substituted cycloalkylamine derivatives and their use as calcium channel antagonists Grant 5,817,698 - Brown , et al. October 6, 1 | 1998-10-06 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 